Jonathan S Katz MD
Neurophysiology
Neurologist, Sutter Pacific Medical Foundation Forbes-Norris MDA/ALS
Join to View Full Profile
2324 Sacramento StSte 111San Francisco, CA 94115
Phone+1 415-600-3604
Fax+1 415-673-5184
Dr. Katz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonResidency, Neurology, 1989 - 1992
Tulane University School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1995 - 2025
TX State Medical License 1993 - 1995
WA State Medical License 1989 - 1994
American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Nov 21
- Clinical Trial Nuedexta in Subjects With ALS Start of enrollment: 2013 Apr 01
- Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial., Jinsy Andrews, Sabrina Paganoni, Eric A Macklin, Lori B Chibnik
JAMA Neurology. 2025-02-17 - Unresolved issues with efgartigimod in CIDP, and broader concerns for future trial design.Jonathan Katz, Liberty Jenkins, David Saperstein
Journal of the Neurological Sciences. 2025-01-15 - 1 citationsMulticenter expanded access program for access to investigational products for amyotrophic lateral sclerosis.Dylan V Neel, Clara Baselga-Garriga, Molly Benson, Mackenzie Keegan, Marianne Chase
Muscle & Nerve. 2024-08-01
Press Mentions
Former Chiropractic Employees Describe What They Say Happened Behind the Scenes at Superior Health CentersSeptember 14th, 2021
Peace over Promise: ALS Patient Quits Taking Drug Aimed at Slowing DiseaseMarch 8th, 2019
First FDA-Approved Treatment for ALS in 22 Years Now Available in U.S.August 8th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
